In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 44, No. 11 ( 2000-11), p. 3155-3157
Abstract:
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) ( n = 300) with that of AZT ( n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
Type of Medium:
Online Resource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.44.11.3155-3157.2000
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
2000
detail.hit.zdb_id:
1496156-8
SSG:
12
SSG:
15,3
Permalink